A Phase 1, Safety Lead-in and Randomized, Open-label, Perioperative Study of Vorasidenib in Combination with Pembrolizumab in Subjects with Recurrent or Progressive Enhancing IDH-1 Mutant Astrocytomas)

Clinical Trial Grant

Duke Scholars

Principal Investigator Katherine Barnett Peters Neurosurgery, Neuro-Oncology

Administered By

Duke Cancer Institute

Awarded By

Servier Pharmaceuticals

Start Date

January 12, 2023

End Date

January 31, 2029

Administered By

Duke Cancer Institute

Awarded By

Servier Pharmaceuticals

Start Date

January 12, 2023

End Date

January 31, 2029